


GENE THERAPY FOR TYPE I DIABETES MELLITUS




Areas of Application

The drug is used for the treatment of type I diabetes in endocrinology medical institutions

Specification

The drug is based on polycations and recombinant DNA complexes containing the human preproinsulin gene. The preparation is prepared ex tempore, before administering. The pilot experiments with gene therapy for type I diabetes have been conducted. Positive results of treatment in long-term studies have been obtained



Long-term euglycemia after intrahepatic administration of polymer-DNA complexes in diabetic Landrace pig

Advantages

There are no analogs in Ukraine. A single gene drug administration provides a long-term effect unlike the conventional treatment of type I diabetes mellitus with lifelong daily exogenous insulin injections to patients. The drug manufacturing costs are cheaper than those of similar foreign preparations based on the use of viruses for carrying therapeutic genes. This drug is safer since it is based on non-viral gene transfer system

IPR Protection

IPR2

Stage of Development.

Suggestion for Commercialization

IRL3, TRL2

Seeking for partners for preclinical tests

Contact Information

Olena K. Toporova, Institute of Molecular Biology and Genetics of the NAS of Ukraine; +38 044 526 55 96, e-mail: toporova@imbg.org.ua